Literature DB >> 19708170

Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV.

Patrinee Traisathit1, Jean Yves Mary, Sophie Le Coeur, Sudanee Thantanarat, Sivaporn Jungpichanvanich, Witaya Pornkitprasarn, Vorapin Gomutbutra, Wanmanee Matanasarawut, Wiroj Wannapira, Marc Lallemant.   

Abstract

AIM: Several studies have shown that preterm delivery, a primary cause of perinatal mortality and morbidity, is more frequent in HIV-positive women. This study aimed to determine factors associated with prematurity in HIV-infected women and identify risks for which specific interventions could be targeted.
METHODS: Data were prospectively collected in a clinical trial assessing the efficacy of different zidovudine prophylaxis durations for the prevention of perinatal HIV transmission in Thailand. Characteristics associated with prematurity - delivery before 37 weeks--were assessed using univariate and multivariate logistic regression and were subsequently used to identify subgroups of women at risk.
RESULTS: Among 979 women, independent prematurity risk factors were: viral load <3.5 or >4.5 log copies/mL; hemoglobin > 11.5 g/dL; weight gain <0.25 kg/week; and body mass index <20 kg/m2. These factors allowed us to define four subgroups with an expected probability of prematurity increasing from 3% to 30%. The two subgroups with the highest expected probability of prematurity were considered to be 'at risk' as opposed to the two lowest (odds ratio = 2.6, 95% confidence interval: 1.7-4.0) and the sensitivity and specificity of the prediction were 51% and 71%, respectively.
CONCLUSION: In this study, four risk factors of preterm delivery were identified allowing the identification of subgroups at increasing risk of prematurity. Adequate nutrition and the provision of highly active antiretroviral therapy during pregnancy as recommended by the World Health Organization for the prevention of perinatal transmission for immunocompromised women in resource-constrained countries may reduce the risk of premature delivery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708170     DOI: 10.1111/j.1447-0756.2008.00925.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  4 in total

1.  Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia.

Authors:  K Cherry Liu; Mansour Farahani; Tshililo Mashamba; Muthuhadini Mawela; Jessica Joseph; Nienke Van Schaik; Engela Honey; Michelle Gill; Waasila Jassat; Elizabeth M Stringer; Namiwnga Chintu; Richard G Marlink
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

2.  Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.

Authors:  Kathleen M Powis; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Jean Leidner; Erik van Widenfelt; Claire Moffat; Sikhulile Moyo; Joseph Makhema; Max Essex; Roger L Shapiro
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

3.  Developmental status of human immunodeficiency virus-exposed uninfected premature infants compared with premature infants who are human immunodeficiency virus unexposed and uninfected.

Authors:  Charne Cox; Joanne Potterton; Samantha Rosie
Journal:  S Afr J Physiother       Date:  2020-06-18

4.  Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.

Authors:  Erika Aaron; Alexa Bonacquisti; Leny Mathew; Gregg Alleyne; Laura P Bamford; Jennifer F Culhane
Journal:  Infect Dis Obstet Gynecol       Date:  2012-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.